

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Application No.:	10/529,071
List of Documents Cited by Applicant		Filing Date:	March 24, 2005
		First Named Inventor:	Li et al.
		Group:	Not assigned
		Examiner:	Not assigned
			Attorney Docket No.:



## U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear
/SL/	1	US 2001/0053352	12/20/2001	Yu et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T
/SL/	2	WO 98/35028	8/13/1998	Alemany et al.		
/SL/	3	WO 02/26192	4/4/2002	Van Meir et al.		

## OTHER DOCUMENTS

Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T
/SL/	4	International Search Report corresponding to PCT App. No. PCT/US03/31097 dated April 21, 2004.	
/SL/	5	HUANG ET AL., "A Hypoxia-Selective Oncolytic Adenovirus for Cancer Therapy", <u>I. J. Radiation Oncology, 54(2) Supplement: 122, 2002.</u>	
/SL/	6	LIU ET AL., "Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells", <u>Circulation Research, 77(3): 638, September 1995.</u>	
/SL/	7	SHIBATA ET AL., "Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes", <u>I.J. Radiation Oncology Biol. Phys., 42(4): 913-916, 1998.</u>	



/SL/	8	BOSSHART ET AL., "A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus", <u>Cell</u> , <b>41</b> : 521-530, June 1995.	
/SL/	9	HERNANDEZ-ALCOCEBA ET AL., "New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication", <u>Human Gene Therapy</u> , <b>13</b> : 1737-1750, September 20, 2002.	
/SL/	10	POST ET AL., "A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy", <u>Oncogene</u> , <b>22</b> : 2065-2072, 2003.	
/SL/	11	SHIBATA ET AL., "Development of a hypoxia-responsive vector for tumor-specific gene therapy", <u>Gene Therapy</u> , <b>7</b> : 493-498, 2000.	

EXAMINER /Scott Long/ DATE CONSIDERED 09/08/2007

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-169 U.S. Department of Commerce  
Patent and Trademark Office

## List of Documents Cited by Applicant

Application No.:	10/529,071
Filing Date:	March 24, 2005
First Named Inventor:	Li et al.
Group:	1632
Examiner:	Not assigned
Attorney Docket No.:	180/156 PCT/US

## U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T

## OTHER DOCUMENTS

Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T
/SL/	A	Koshikawa et al. <i>Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells.</i> <i>Cancer Research</i> , Vol. 60, (2000), pp.2936-2941	
/SL/	B	Griffiths et al. <i>The macrophage – a novel system to deliver gene therapy to pathological hypoxia.</i> <i>Gene Therapy</i> , Vol. 7, (2000), pp.255-262	
/SL/	C	Kurihara et al. <i>Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.</i> <i>The Journal of Clinical Investigation</i> , Vol. 106, no. 6, (2000), pp.763-771	

/SL/	D	Kruyt et al. <i>Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis.</i> <i>Human Gene Therapy</i> , Vol. 13, (2002), pp.485-495	
/SL/	E	Supplementary Partial European Search Report corresponding to EP application No. EP 03799374 dated November 24, 2006.	

EXAMINER /Scott Long/ DATE CONSIDERED 09/08/2007

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


**FORM PTO-1449 U.S. Department of Commerce**  
**Patent and Trademark Office**
**List of Documents Cited by Applicant**

Application No.:	10/529,071
Filing Date:	March 24, 2005
First Named Inventor:	Li et al.
Group:	1632
Examiner:	Not assigned
Attorney Docket No.:	180/156 PCT/US

**U.S. PATENT DOCUMENTS**

Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T

**OTHER DOCUMENTS**

Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T
/SL/	A	EP Office Action corresponding to an EP Patent Application No. 03799374.8 dated April 19, 2007	
/SL/	B	Indian Office Action corresponding to an IN Patent Application No. 1197//DELNP/2005 dated April 9, 2007	

EXAMINER /Scott Long/ DATE CONSIDERED 09/08/2007

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.